Glycosaminoglycans oral therapy reduces microalbuminuria, blood fibrinogen levels and limb arteriopathy clinical signs in patients with non-insulin dependent diabetes mellitus

Diabetes, Nutrition and Metabolism - Clinical and Experimental

Volumn 9, Issue 2, 1996, Pages 53-58

  Velussi, M ^a,b   Cernigoi, A M ^a   Dapas, F ^a   De Monte, A ^a  

^a Monfalcone Hospital   (Italy)

^b Ospedale di Monfalcone   (Italy)

Author keywords

Fibrinogaenemia; Limb arteriopathy; Microalbuminuria; NIDDM; Oral glycosaminoglycans

Indexed keywords

ANTIDIABETIC AGENT; FIBRINOGEN; GLYCOSAMINOGLYCAN; SULFONYLUREA; SULODEXIDE;

ADULT; AGED; ARTICLE; CLAUDICATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIABETIC ANGIOPATHY; DRUG EFFICACY; FEMALE; FIBRINOGEN BLOOD LEVEL; HUMAN; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; WALKING;

EID: 0029922805     PISSN: 03943402     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Mogensen C.E., Chachati A., Christiensen C.H., Close C.F., Deckert T., Hommel E., Kastrup J., Lefebvre P., Mathiesen E.M., Rassmussen B., Smith A., Viberti G.C.: Microalbuminuria: an early marker of renal involvement in diabetes. Uremia Invest. 9: 85-95, 1985-86.
2. Knoebl P., Schernthaner G., Schnack C., Pietschmann P., Griesmacher A., Prager R., Muller M.: Thrombogenic factors are related to urinary albumin excretion rate in Type 1 (insulin-dependent) and Type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36: 1045-1050, 1993.
3. National Diabetes Data Group: Classification and diagnosis of diabetes mellitus and other cathegories of glucose intolerance. Diabetes 28: 1039-1057, 1979.
4. Keen H., Jarrett R.J.: The WHO multinational study of vascular disease in diabetes. Macrovascular disease prevalence. Diabetes Care 2: 187-195, 1979.
5. Blach K.W., Srandness D.E. Jr.: Arteriosclerosis obliterans and associated risk factors in insulin-dependent and non insulin-dependent diabetes. Diabetes 29: 882-888, 1980.
6. Ceriello A.: Coagulation activation in diabetes mellitus: the role of hyperglycaemia and therapeutics prospects. Diabetologia 36: 1119-1125, 1993.
7. Ceriello A., Taboga C., Tonutti L., Motz G., Giacomelli R., Stel G., Folleti F., Zoratti R., Lizzio S., Bortoli E.: Oxidative stress and vascular thrombosis in diabetes mellitus. Diabetologia 37 (Suppl. 1) A54: 207, 1994 (Abstract).
8. Wolff S.P.: Diabetes mellitus and free radicals - Free radicals, transition metals and oxidative stress in the aetiology of diabetes mellitus and complications. Br. Med. Bull. 49: 642-652, 1993.
9. Gruden G., Olivetti R., Romagnoli R., Frezet D., Cavallo Perin P., Pagano G.: Thrombomodulin is increased in microalbuminuric insulin-dependent diabetic patients. Diabetologia 37 (Suppl. 1) A 194: 747, 1994 (Abstract).
10. Matello M., Boeri D., Podesta F., Cagliero E., Vichi M., Odetti P., Adezati L., Lorenzi M.: Increased expression of tissue plasminogen activator and its inhibitor and reduced fibrinolytic potential of human endothelial cells cultured in elevated glucose. Diabetes 41: 1009-1015, 1992.
11. Collier A., Rumley A.: Free radical activity and hemostatic factors in NIDDM patients with and without microalbuminuria. Diabetes 41: 909-913, 1992.
12. Van den Born J., van Kraats A., Bakker M.A.H., Assmann K.J.M., Dijkinen H.B., van der Laak J.A., Berden J.H.: Glomerular basement membrane heparan sulfate alterations in experimental diabetic nephropathy. Diabetologia 37 (Suppl. 1) A35: 132, 1994 (Abstract).
13. Oturai P.S., Rasch R., Johansen M., Yokoyama H., Thornssen M.K., Myrup B., Kofoed-Enevolsen A., Deckert T.: Low dose heparin treatment prevents glomerular basement membrane thickening in diabetic rats. Diabetologia 37 (Suppl. 1) A14: 47, 1994 (Abstract).
14. Gambaro G., Cavazzana A.O., Luzi P., Piccoli A., Borsatti A., Crepaldi G., Marchi E., Venturini A.P., Baggio B.: Glycosaminoglycans prevent morphological renal alterations and albuminuria in diabetic rats. Kidney Int. 42: 285-291, 1992.
15. Gambaro G., Venturini A.P., Noonan D.M., Fries W., Re G., Garbisa S., Milanesi C., Pesarini A., Borsatti A., Marchi E., Baggio B.: Treatment with a glycosaminoglycan formulation ameliorates experimental diabetic nephropathy. Kidney Int. 46: 797-806, 1994.
16. Myrup B., Hansen P.M., Jensen T., Kofoed-Enevolsen A., Feldt-Rasmussen B., Gram J., Kluft E., Jespersen J., Deckert T: Low molecular weight heparin lowers elevated albumin excretion in Type 1 diabetes mellitus. Diabetologia 37 (Suppl. 1) A188: 724, 1994 (Abstract).
17. Ceriello A., Quatraro A., Marchi E., Barbanti M., Giugliano D.: Impaired fibrinolytic response to increased thrombin activation in Type I diabetes mellitus: effects of the glycosaminoglycan sulodexide. Diabete Metabolisme 19: 225-229, 1993.
18. Ceriello A., Quatraro A., Ettorre M., Marchi E., Barbanti M., Giugliano D.: Glucosaminoglycans administration decreases high fibrinogen plasma levels in diabetic patients. Diab. Nuir. Metab. 6: 1-4, 1993.
19. Sola G.,Valle I.: II Sulodexide nel trattamento delle arteriopatie periferiche croniche. Gazz. Med.It. 145: 91-98, 1986.
20. Palmieri G., Nazzari M., Ambrosi G., Campiotti A., Palazzini E.: Sulodexide in the treatment of peripheral arterial disease. Clin. Trials J. 21: 411-427, 1984.
21. Daprati A., Alaimo A., Cascone G.: Valutazione clinico-farmacologica del sulodexide in pazienti diabetici. Therapeutika 1: 191-196, 1984.
22. Mazzi C., Mainini E., Morandi G., Martinelli I.: Effetto del sulodexide sui fattori determinanti della micro- e macroangiopatia diabetica: studio clinico-metabolico. Farmaci 8: 439-448, 1984.
23. Piva I., Lora L., Basso A., Erle G.: Studio controllato dell'effetto del sulodexide nella macroangiopatia diabetica periferica Gtorn. Clin. Med. 66: 37-45, 1985.
24. Parodi F., Cataldi L.: II sulodexide nelle vasculopatie arteriosclerotiche periferiche dei diabetici. G. Gerontol. 33: 237-242, 1985.
25. Amoretti R., Teodonio C.: Sulodexide e macroangiopatia diabetica. Studio clinico. Agg. Med. Chir. 3: 1-6, 1985.
26. Giorgt Pierfranceschi D.: Effeito del sulodexide su alcuni fattori di rischio metabolici nella macroangiopatia diabetica. Farmaco, Ediz. Prat. 61: 67-76, 1986.
27. Negrini F., Botrugno A., Gerali P.: A study of the clinical, antithrombotic and hemorrheologic activity of sulodexide in patients with diabetic vasculopathy. Farmaci Terapia 3: 130-134, 1986.
28. Ultratova J., Mayer J., Elbl L.: Experience with the preparation sulodexide in diabetics with ischaemic affections of the lower extremities. Vnütrni lékarství 39: 575-580, 1993.
29. Baggio B., Gambaro G.: Antiproteinuric effect of glycosaminoglycans? (letter) Nephron. 64: 643-644, 1993.
30. Solini A., Carraro A., Barzon I., Crepaldi G.: Therapy with glycosaminoglycans lowers albumin excretion rate in noninsulin dependent diabetic patients with macroalbuminuria. Diab. Nutr. Metab. 7: 304-307, 1994.
31. Markell M.S., Friedman E.A.: Diabetic nephropathy. Management of the end-stage patient. Diabetes Care 15: 1226-1238, 1992.
32. Van den Born J., Van Kraats A.A., Bakker M.A.H., Assmann K.J.K., van den Heuvel L.P., Veerkamp J.H., Berden J.H.M.: Selective proteinuria in diabetic nephropathy in the rat is associated with a relative decrease in glomerular basement membrane heparan sulphate. Diabetologia 38: 161-172, 1995.
33. Tamsma J.T., Van den Born J., Bruijn J.A., Assmann K.J.M., Weening J.J., Berden J.H.M., Wieslander J., Schrama E., Hermans J., Veerkamp J.H., Lemkes H.H., van der Woude F.J.: Expression of glomerular extracellular matrix components in human diabetic nephropathy: decrease of heparan sulphate in the glomerular basement membrane. Diabetologia 37: 313-320, 1994.
34. Deckert T., Feldt-Rasmussen B.: Albuminuria reflects widespread vascular damage. The Steno Hypothesis. Diabetologia 32: 219-226, 1989.
35. Moraro S., Pietravalle P., De Rossi M.G., Monari G., Cristina G., Medici E., Sensi M., Andreani D., Di Mario U.: A charge selectivity impairment in protein permselectivity is present in Type 2 diabetes mellitus. Acta Diabetol. 39: 138-142, 1993.
36. Gambaro G., Baggio G.: Role of glycosaminoglycans in diabetic nephropathy. Acta Diabetol. 29: 149-155, 1992.
37. Myrup B., Hansen P.N., Jensen T., Kofoed-Enevoldsen A., Feldt-Rasmussen B., Gram J., Kluft C., Jespersen J., Deckert T.: Effect of low-dose heparin on urinary albumin excretion in insulin-dependent diabetes mellitus. Lancet 345: 421-422, 1995.
38. Crepaldi G., Fellin R., Calabrò A., Rossi A., Ventura A., Mannarino E., Senin U., Ciuffetti G., Descovich G.C., Gaddi A., Rimondi S., Pozza G., Vicari A., Carandente O., Mancini M., Rubba P., Postiglione A., Strano A., Avellone G., Davì G., Novo S., Pinto A., Capurso A., Resta F., Mogavero A.M., Bucci A., Antonini R., Lalloni L.: Double-blind multicenter trial of a new medium molecular weight glycosaminoglycan. Current therapeutic effects and perspectives for clinical use. Atherosclerosis 81: 233-243, 1990.
39. Agrati A.M., Mauro M., Savasta C., Palmieri G.C.: A double-blind, cross-over, placebo-controlled study of the profibrinolytic and antithrombotic effects of oral sulodexide. Adv. Ther. 9: 147-155, 1992.
40. Lunetta M., Salanitri T.: Lowering of plasma viscosity by the oral administration of the glycosaminoglycan sulodexide in patients with Peripheral Vascular Disease. J. Int. Med. Res. 20: 44-53, 1992.
41. Schmitz A., Ingerslev J.: Haemostatic measurements in type 2 diabetic patients with microalbumunuria. Diabetic Med. 7:521-525, 1990.
42. Knoebl P., Scherntaner G., Schnack C., Pietschmann P., Griesmacher A., Prager R., Muller M.: Thrombogenic factors are related to urinary albumin excretion rate in Type 1 (insulin-dependent) and Type 2 (non insulin-dependent) diabetic patients. Diabetologia 36: 1045-1050, 1993.